Positive results of NuvOx Pharma’s NanO2 (DDFPe) in the treatment of stroke have been published at the International Stroke Conference. A randomized Phase Ib/II trial tested acute ischemic stroke patients given placebo or low, medium, or high doses of NanO2. The primary endpoint was safety, which was demonstrated at all three dose levels. A secondary endpoint was the modified Rankin Scale (mRS), a measure of how independently patients can live in the weeks and months after the stroke. The high dose group suggested improvement in the mRS at 30 days and 90 days.
top of page
Search
Recent Posts
See AllTucson, AZ, September 6th, 2024 – NuvOx Pharma LLC, a wholly owned subsidiary of NuvOx Therapeutics Inc. (together, “NuvOx”) announced...
Tucson, AZ, June 30th, 2024 – NuvOx Pharma LLC (“NuvOx”) announced that it has received authorization from Health Canada for its EXTEND:...
Tucson, AZ, January 2, 2024 - NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and...
bottom of page
Comments